| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0009-9236(97)90114-4 |
| P698 | PubMed publication ID | 9357387 |
| P50 | author | Reginald F. Frye | Q37370763 |
| P2093 | author name string | Porter JA | |
| Matzke GR | |||
| Branch RA | |||
| Adedoyin A | |||
| P2860 | cites work | Interindividual variations in drug disposition. Clinical implications and methods of investigation | Q71064667 |
| Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection | Q71791319 | ||
| Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo* | Q71809403 | ||
| Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography | Q71910987 | ||
| Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans | Q72031980 | ||
| High-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in serum: a tool for indirect evaluation of cytochrome P4502E1 activity in humans | Q72273045 | ||
| Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population | Q72415309 | ||
| Cocktail strategy: complications and limitations | Q72756021 | ||
| Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients | Q28379555 | ||
| Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis | Q34346052 | ||
| Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man. | Q34358130 | ||
| Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach | Q34418061 | ||
| Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. | Q34447859 | ||
| Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism | Q35824374 | ||
| Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial | Q36737411 | ||
| The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms | Q37911387 | ||
| Metronidazole and antipyrine as probes for the study of foreign compound metabolism | Q37918077 | ||
| A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans | Q37946157 | ||
| Genetic polymorphism of S-mephenytoin hydroxylation | Q38692055 | ||
| Assessment of liver metabolic function. Clinical implications | Q40648534 | ||
| Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease | Q41103327 | ||
| Influence of diet and nutritional status on drug metabolism | Q41128208 | ||
| N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity | Q42000770 | ||
| Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. | Q42281878 | ||
| Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism | Q42285032 | ||
| Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine | Q43222504 | ||
| The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects | Q44986835 | ||
| Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach | Q45278849 | ||
| Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children | Q46589719 | ||
| Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. | Q51595767 | ||
| Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine | Q56832433 | ||
| Influence of renal failure on cytochrome P 450 activity in hypertensive patients using a "cocktail" of antipyrine and nifedipine | Q62542310 | ||
| Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1 | Q67260608 | ||
| The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer | Q67837223 | ||
| Simplified phenotyping with dextromethorphan by thin-layer chromatography: application to clinical laboratory screening for deficiencies in oxidative drug metabolism | Q67985969 | ||
| Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans | Q68034171 | ||
| The disposition of dapsone in cirrhosis | Q68167904 | ||
| Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide | Q68411894 | ||
| Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin | Q68921104 | ||
| S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin | Q69610224 | ||
| The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women | Q70490332 | ||
| Comparison of hepatic drug-oxidizing activity after simultaneous administration of two probe drugs, caffeine and trimethadione, to human subjects | Q70581297 | ||
| Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism | Q70670623 | ||
| Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1 | Q70766730 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 365-376 | |
| P577 | publication date | 1997-10-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes | |
| P478 | volume | 62 |
| Q35640730 | "Cocktail" approaches and strategies in drug development: valuable tool or flawed science? |
| Q42758567 | A UPLC-MS/MS assay of the "Pittsburgh cocktail": six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution |
| Q42284131 | A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study |
| Q33324419 | A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. |
| Q28365904 | An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A) |
| Q24621760 | Applications of CYP450 testing in the clinical setting |
| Q37249682 | Applications of metabolomics in drug discovery and development |
| Q36720920 | Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach |
| Q46856522 | Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity |
| Q73299939 | CYP2D6 mutations and therapeutic outcome in schizophrenic patients |
| Q56795476 | Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls |
| Q41925505 | Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail |
| Q44893470 | Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method |
| Q36926307 | Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. |
| Q35765836 | Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba |
| Q24657536 | Clinical use of pharmacogenomic tests in 2009 |
| Q34417621 | Clinical-pharmacological strategies to assess drug interaction potential during drug development |
| Q46896698 | Comparative studies of the effects of two novel sugar drug candidates on the CYP 1A2 and CYP 2E1 enzymes in different sexed rats using a "cocktail" approach |
| Q46616703 | Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction |
| Q89964241 | Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo |
| Q51432740 | Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. |
| Q48610657 | Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo |
| Q37314453 | Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteers |
| Q37034724 | Effect of Repeated Wuniu Early Tea Administration on the CYP450 Activity Using a Cocktail Method |
| Q41906399 | Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects |
| Q36053651 | Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine |
| Q37399585 | Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach |
| Q58817150 | Effect of liver disease on dose optimization |
| Q43024689 | Effect of nicotine on cytochrome P450 1A2 activity. |
| Q42283286 | Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity |
| Q34228674 | Effect of pharmacogenetics on medicine |
| Q33789233 | Effects of liver disease on pharmacokinetics. An update |
| Q43032104 | Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. |
| Q35051403 | Enantioselective analytical methods in pharmacokinetics with specific reference to genetic polymorphic metabolism |
| Q50035868 | Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study |
| Q36387998 | Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. |
| Q46862480 | Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers |
| Q32079778 | High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. V. Validation of a direct injection/on-line guard cartridge extraction--tandem mass spectrometry method for CYP1A2 inhibition assessment |
| Q74229453 | High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy. I. Development of direct injection/on-line guard cartridge extraction/tandem mass spectrometry for the simultaneous detection of CYP probe substrates and |
| Q43620137 | High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy: III. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP2C19 inhibition evaluation |
| Q73025601 | High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessme |
| Q37622756 | In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. |
| Q34300898 | Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation |
| Q46981888 | Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial |
| Q36068699 | Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. |
| Q36323058 | Microsome biocolloids for rapid drug metabolism and inhibition assessment by LC-MS |
| Q92077259 | No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug-Drug Interaction Study |
| Q39906127 | Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug-Drug Interactions Involving Modafinil |
| Q33781271 | Pharmacogenetics of cytochromes P450. |
| Q35825950 | Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. |
| Q80577452 | Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations |
| Q46605128 | Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population |
| Q35827434 | Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone |
| Q35579407 | Principles and clinical application of assessing alterations in renal elimination pathways. |
| Q44194942 | Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatography-electrospray ionization-ion trap mass spectrometry |
| Q37184530 | Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans |
| Q41737190 | Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers. |
| Q47722127 | Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. |
| Q44228277 | Stereoselective determination of the CYP2C19 probe drug mephenytoin in human urine by gas chromatography-mass spectrometry. |
| Q35049310 | Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. |
| Q42868963 | Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women |
| Q35129048 | The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective |
| Q86705072 | The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots |
| Q53478527 | The legacy of pharmacogenetics and potential applications. |
| Q90599845 | Understanding the relevance of herb-drug interaction studies with special focus on interplays: a prerequisite for integrative medicine |
| Q38726643 | Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. |
Search more.